295 reports of suspected side effects of implants in 2023 In 2023, 295 individuals reported one or more suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI).
RIVM recommends a standardised design for e-cigarettes to reduce e-cigarette appeal Features like a sleek design, technical add-ons such as Bluetooth, and ease of concealment are examples that make e-cigarettes attractive to young people, according to research by RIVM. That is why RIVM recommends policymakers to consider implementing a standardised design for e-cigarettes
RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Menno de Jong appointed director of RIVM Centre for Infectious Disease Control Starting 1 May 2024, Professor Menno de Jong will take on the role of director of RIVM’s Centre for Infectious Disease Control (CIb) . He succeeds Jaap van Dissel, who is retiring in April 2024.
Nitrogen and nature approach shows progress towards 2030, but targets are out of reach The nitrogen and nature measures that the government has implemented since 2021 are expected to make a positive contribution to the future quality of nature. The average exceedance of the critical loads for nitrogen deposition will decrease by a third up to 2030.
No changes to chromium (VI) adverse health effect list No changes will be made to the list of adverse health effects that may be caused by exposure to chromium (VI) in the workplace. According to RIVM, the latest scientific literature has resulted in no new insights.
Natura 2000 sites: nitrogen deposition on the decline, but still too high for much of nature The amount of nitrogen deposited on nature reserves that are vulnerable to this is falling. However, this decline is not sufficient to meet the targets the Dutch government has set itself. This is the conclusion of the RIVM monitoring report ‘Nitrogen deposition in Natura 2000 areas 2023’.
Participation rates in cancer population screening programmes continue to decline The number of participants in the population screening programmes for breast cancer, cervical cancer and colorectal cancer continues to decline. This decline has been going on for years, reaching its lowest point in 2020.
Metabolic disorder ALD added to newborn blood spot screening Since 1 October, the metabolic disorder adrenoleukodystrophy (ALD) has been added to the Dutch newborn blood spot screening. From now on, the blood of newborn boys will also be tested for this disorder. ALD in boys can be treated if it is detected in time.
COVID-19 vaccination for risk groups: over-60s, flu vaccine group, care workers and pregnant women From 19 September 2023 on, the first people will receive an invitation for COVID-19 vaccination. The first invitations will be sent by RIVM to people aged 60 years and older.